论文部分内容阅读
用培养７ｄ以上的ＣＤ３单抗激活的杀伤细胞（ＣＤ３ＡＫ细胞）加ｒＩＬ－２静注治疗晚期肝癌２１例，其中ＣＲ１例，ＰＲ５例，临床有效率以ＣＲ＋ＰＲ计为２８．９％，明显高于ＬＡＫ细胞抗肝癌疗效。治疗后大多数病人临床症状改善，生活质量提高，外周血ＣＤ３＋、ＣＤ４＋升高，ＣＤ８＋下降，ＣＤ４＋／ＣＤ８＋升高，统计学检验均有显著差异。患者血清ＳＩＬ－２Ｒ水平明显降低（Ｐ＜０．０１）。结果提示：静脉注射ＣＤ３ＡＫ细胞可以降低肝癌患者机体瘤负荷，增强机体免疫力，从而对晚期肝癌产生较好的治疗效果。
Intracoronary injection of CD3AK cells and rIL-2 activated by CD3 monoclonal antibody cultured for more than 7 days treated 21 cases of advanced hepatocellular carcinoma, including CR1 cases and PR cases, and the clinical effective rate was 28.9%, which was significantly higher than that of CR+PR. LAK cells have anti-liver cancer effect. After treatment, most patients had improved clinical symptoms, improved quality of life, elevated CD3+, CD4+ in the peripheral blood, decreased CD8+, and increased CD4+/CD8+. There were significant differences in statistical tests. Serum SIL-2R levels were significantly lower in patients (P<0.01). The results suggest that intravenous injection of CD3AK cells can reduce the body tumor burden of liver cancer patients, enhance the body’s immune system, and thus produce a better therapeutic effect on advanced liver cancer.